Radium-223, an alpha emitter, but not strontium-89, a beta emitter, improves survival and decreases the risk of symptomatic skeletal events in patients with bone metastases from castration-resistant prostate cancer, a meta-analysis found.
The American College of Sports Medicine reconvened the ACSM Roundtable to update its guidelines for prescribing exercise for patients and survivors of cancers.
For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
Even though the EMBRACE study adds to the literature, according to authors the “best way” to screen men with germline DNA damage repair abnormalities “remains unclear.”
